Latest Publicaitons
HYTN Announces Closing of Non-Brokered Private Placement Under Listed Issuer Financing Exemption
HYTN is pleased to announce that it has closed its previously announced nonbrokered private placement of units of the Company (“Units”) by issuing a total of 5,050,000 Units at a price of $0.10 per Unit (the “Offering”) for aggregate gross proceeds of $505,000.
HYTN Announces Non-Brokered Private Placement Under Listed IssuerFinancing Exemption
HYTN is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.10 per Unit…
HYTN Innovations Announces the Resignations of Vic Neufeld and Dennis Staudt from the Board of Directors
HYTN announced today the immediate resignations of Vic Neufeld and Dennis Staudt from their positions as members of the Board of Directors (the "Board").
HYTN Innovations expands its Controlled Drugs and Substances Dealers License to include MDMA and Ketamine
HYTN Innovations Inc. announced today that it has submitted an amendment to its Controlled Drugs and Substances Dealers License with Health Canada…
HYTN Innovations Cultivates Psilocybin Mushrooms and Upgrades Equipment for API Development
HYTN Innovations Inc. announced that it has successfully initiated cultivation of psilocybin mushrooms…
HYTN Innovations Advances Active Pharmaceutical Ingredient Portfolio andIncreases Sales of Rapid Onset Cannabis Products Using Proprietary ElevationTechnology®
HYTN Innovations Inc., a leading manufacturer of products containing psychoactive and psychotropic compounds…
HYTN Sells Out of Innovative Holiday Products
HYTN Cannabis Inc., has achieved 100% purchase fulfillment of its holiday specific offerings, delivering festive flavours to cannabis…
HYTN Initiates Sale of Cannabis Products in Quebec Through Agreement With Rose
HYTN Cannabis Inc., has entered into a sales, distribution and marketing agreement with Rose LifeScience Inc., a leading supplier of cannabis products in Quebec.
HYTN Awarded Controlled Drugs and Substances Dealer’s License Allowing for Production and Sale of Psilocybin
HYTN Cannabis Inc., has been awarded a Controlled Drugs and Substances Dealer’s Licence (the “License”) by Health Canada allowing for the sale, possession, production, assembly and transportation of psilocybin…
HYTN Opens Provincial and Territorial Markets for Tricanna Manufactured Pre-Rolled Cannabis Products
HYTN Cannabis Inc., has entered into a manufacturing agreement with Tricanna Industries Inc., a leading supplier of pre-rolled cannabis products.
HYTN Awarded Medical Cannabis Sales Licence Increasing Opportunities at Kelowna Facility
HYTN Cannabis Inc., has been awarded a license by Health Canada allowing for the sale of cannabis for medical purposes (with possession).
HYTN Secures Cannabis Cultivation Licence to Elevate the Quality of its Cannabis Inputs
HYTN Cannabis Inc., has received a license amendment (the “License Amendment”) from Health Canada allowing for the cultivation of cannabis. This License Amendment further strengthens…
HYTN Innovations Inc. Reports Q2 Results
The Q2 Results reflect the details of HYTN’s reverse-take-over (“RTO”) of Mount Dakota Energy Corp. and the Company’s financial position post-RTO. The Company notes that the complexity of the Q2 Results…
HYTN Accelerates Sales Growth Through Atlantic Canada Distribution
Nova Scotia represents significant incremental points of sale for HYTN products, which feature their proprietary Elevation Technology and are produced at the Company’s wholly-owned, purpose-built…
HYTN Grows Exports with Cannabis Flower Sales to Australia
Leveraging our partnerships and our licensed manufacturing facility, we have entered the dry flower space and executed on procuring, drying, curing and exporting dry flower and obtaining the…
HYTN Begins Accepting Orders Directly from Provinces and Territories
This news builds on HYTN’s February 22 announcement that it had been awarded approval to sell cannabis products to provincially and territorially authorized retailers and that the Company…
HYTN Reports Q1 Financial Results for the Quarter Ending Dec 31, 2021
The Q1 Results demonstrate HYTN’s path to commercialization as HYTN Beverage generated total sales of $212,581 during the Q1. This swift path to revenue was achieved as a direct result completion…